Corcept Therapeutics

(NASDAQ) CORT

Current Price$89.82

Market Cap$9.62B

Since IPO (2004)+632%

5 Year+344%

1 Year+23%

1 Month+7%

Corcept Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 89.72	2026-07-16

Corcept Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.79%	USD 93.25	2026-07-09
1 month	+7.18%	USD 83.71	2026-06-16
3 month	+94.37%	USD 46.16	2026-04-17
Year to date	+157.82%	USD 34.80	2025-12-31
1 year	+23.16%	USD 72.85	2025-07-16
3 year	+291.11%	USD 22.94	2023-07-17
5 year	+344.16%	USD 20.20	2021-07-16
Since inception	+632.38%	USD 12.23	2004-04-14

Corcept Therapeutics Financials at a Glance

Market Cap

$9.62B

Revenue (TTM)

$769.10M

Net Income (TTM)

$47.90M

EPS (TTM)

$0.35

P/E Ratio

255.91

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$89.82

Volume

878,106

Open

$89.69

Price

$89.82

Volume

878,106

Open

$89.69

Previous Close

$89.72

Daily Range

$88.86 - $92.64

52-Week Range

$28.66 - $95.11

Estimated Earnings Date

Jul 30, 2026

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$89.82

Volume

878,106

Open

$89.69

Previous Close

$89.72

Daily Range

$88.86 - $92.64

52-Week Range

$28.66 - $95.11

Estimated Earnings Date

Jul 30, 2026

CORT News

Page 1

CORT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Corcept Therapeutics

Corcept helps people who have serious health problems caused by too much cortisol, a stress hormone. It sells a daily pill to manage high blood sugar in patients with a condition called Cushing’s syndrome. The company also creates new medicines to treat cancer and other severe illnesses.

The Product Portfolio

Korlym: Once-daily oral medicine for adults with Cushing’s syndrome who have high blood sugar and cannot have surgery.
Authorized Generic: Cheaper version of Korlym made available in June 2024 for the same patient group.
Selective Modulators: Pipeline of over 1,000 compounds designed to block cortisol effects without the side effects of older drugs.

New Paths and Partnerships

Submitted an application to the FDA in July 2025 for relacorilant to treat platinum-resistant ovarian cancer.
Transferred specialty pharmacy services to Curant Health Georgia, LLC in late 2025 to support patient drug distribution.
Completed enrollment for the MONARCH trial in October 2023 to study miricorilant as a treatment for liver disease.
Partnered with the research group ARCAGY-GINECO to start a cervical cancer study in early 2026.

What Makes Corcept Different?

Corcept owns over 1,000 proprietary compounds that target specific hormone receptors while avoiding others to reduce patient side effects. The company maintains a patient support program to ensure no one is denied treatment for financial reasons.

Growth by the Numbers

Revenue reached $202.1 million in Q4 2025, up 11.1% from Q4 2024.
Operating income was $4.5 million in Q4 2025, down 82.2% from $25.3 million in Q4 2024.
Net income hit $24.3 million in Q4 2025, a 20.1% decrease from the previous year.
Free cash flow hit $38.4 million in Q4 2025, up 552.3% from the same period two years ago.
Research and development spending was $254.9 million in 2025, representing 36% of total operating expenses.

Bottom Line

Corcept has moved from a single-product company to a clinical-stage developer testing drugs for cancer, ALS, and liver disease. This shift from one niche treatment to a broad research pipeline defines its current business strategy.

AI Generated • Apr 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

730

CEO

Joseph K. Belanoff, MD

Website

www.corcept.com

Headquarters

Menlo Park, CA 94025, US

CORT Financials

Key Financial Metrics (TTM)

Gross Margin

98.25%

Operating Margin

-1.07%

Net Income Margin

6.23%

Return on Equity

7.50%

Return on Capital

6.85%

Return on Assets

5.88%

Earnings Yield

0.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.62B

Shares Outstanding

107.35M

Volume

878.11K

Avg. Volume

1.10M

Financials (TTM)

Gross Profit

$755.64M

Operating Income

-$8.22M

EBITDA

$14.16M

Operating Cash Flow

$120.10M

Capital Expenditure

-$308.00K

Free Cash Flow

$119.79M

Cash & ST Invst.

$338.18M

Total Debt

$9.64M

Corcept Therapeutics Performance Analysis

Corcept Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 401,858,000	9.8%
2023	2023-12-31	USD 482,375,000	20.0%
2024	2024-12-31	USD 675,040,000	39.9%
2025	2025-12-31	USD 761,407,000	12.8%

Corcept Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	23.7%
Q3	2025-09-30	6.8%
Q4	2025-12-31	-2.7%
Q1	2026-03-31	-18.4%

Corcept Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.87	-2.2%
2023	2023-12-31	USD 0.94	8.1%
2024	2024-12-31	USD 1.23	30.4%
2025	2025-12-31	USD 0.82	-33.5%

Corcept Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	70.6%
Q3	2025-09-30	-44.8%
Q4	2025-12-31	25.0%
Q1	2026-03-31	-250.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$164.90M

+4.9%

Gross Profit

$162.02M

+4.7%

Gross Margin

98.25%

N/A

Market Cap

$9.62B

N/A

Market Cap/Employee

$13.17M

N/A

Employees

730

N/A

Net Income

-$31.20M

-251.9%

EBITDA

-$44.12M

-537.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$338.18M

+4.8%

Total Debt

$9.64M

+41.0%

Accounts Receivable

$39.07M

-53.7%

Inventory

$12.89M

-10.3%

Long Term Debt

$8.01M

+36.9%

Short Term Debt

$1.63M

+65.3%

Return on Assets

5.88%

N/A

Return on Invested Capital

-1.23%

N/A

Free Cash Flow

-$16.97M

-437.8%

Operating Cash Flow

-$16.77M

-427.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CYTKCytokinetics, Incorporated

CYTKCytokinetics, Incorporated$80.36-2.74%

HALOHalozyme Therapeutics, Inc.

HALOHalozyme Therapeutics, Inc.$77.54+2.27%

NUVLNuvalent, Inc.

NUVLNuvalent, Inc.$123.96+0.00%

ABVXAbivax S.A.

ABVXAbivax S.A.$137.77+0.61%

RYTMRhythm Pharmaceuticals, Inc.

RYTMRhythm Pharmaceuticals, Inc.$106.09-3.28%

AXSMAxsome Therapeutics, Inc.

AXSMAxsome Therapeutics, Inc.$237.04-0.21%

MRUSMerus N.V.

MRUSMerus N.V.$90.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.60-0.00%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

NOKNokia

NOKNokia$10.38-0.08%

ONDSOndas

ONDSOndas$6.65-0.06%

INTCIntel

INTCIntel$96.98-0.06%

PATHUiPath

PATHUiPath$12.03+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.32-0.03%

Questions About CORT

What is the current price of Corcept Therapeutics?

Corcept Therapeutics is trading at $89.72 per share.

What is the 52-week range for Corcept Therapeutics?

Over the past 52 weeks, Corcept Therapeutics has traded between $28.66 and $95.11.

How much debt does Corcept Therapeutics have?

As of the most recent reporting period, Corcept Therapeutics reported total debt of $9.64M.

How much cash does Corcept Therapeutics have on hand?

Corcept Therapeutics reported $108.74M in cash and cash equivalents in its most recent financial results.

What is Corcept Therapeutics’s dividend yield?

Corcept Therapeutics does not currently have a dividend yield.

Corcept Therapeutics

Corcept Therapeutics Financials at a Glance

CORT News

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

5 Best Biotech ETFs for 2026 and How to Invest

Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday

Corcept Insider Transaction Explained After Shares Tumble 50% in One Day

Why Corcept Therapeutics Plummeted by 50% Today

3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin

Why Corcept Therapeutics Stock Was Up 11.6% Friday

CORT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Corcept Therapeutics

The Product Portfolio

New Paths and Partnerships

What Makes Corcept Different?

Growth by the Numbers

Bottom Line

CORT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Corcept Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CORT

What is the current price of Corcept Therapeutics?

What is the 52-week range for Corcept Therapeutics?

How much debt does Corcept Therapeutics have?

How much cash does Corcept Therapeutics have on hand?

What is Corcept Therapeutics’s dividend yield?

Premium Investing Services